8-K: Vivos Inc. Appoints New President and COO

Vivos Inc. announced the appointment of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, strengthening its leadership in targeted cancer therapies.

Summary

• Vivos Inc. appointed Brad Allan Weeks as President, effective September 1, 2025, with a term ending December 31, 2027.
• Mr. Weeks will receive an annual base salary of $192,000 and a monthly grant of $3,000 in common stock shares, based on the closing price at the end of each fiscal quarter.
• David J. Swanberg was appointed Chief Operating Officer, effective September 1, 2025, with a term ending December 31, 2028.
• Mr. Swanberg will receive a consulting rate of $12,000 per month and a monthly grant of $3,000 in common stock shares, based on the closing price at the end of each fiscal quarter.
• Both appointments include customary benefits, reimbursement for reasonable out-of-pocket business expenses, and provisions relating to confidentiality, non-competition, and non-solicitation.

Sentiment

Score: 8

Explanation: The appointments of highly experienced and qualified individuals to key leadership positions (President and COO) are a strong positive signal for the company's strategic direction and operational execution in the specialized field of targeted cancer therapies. Both individuals bring relevant prior experience, including direct involvement with Vivos Inc. or comparable industry success, which should instill confidence in investors regarding future growth and development.

Positives

• The appointment of Brad Allan Weeks as President brings extensive experience in the medical device and biotechnology sectors, focusing on business development, team expansion, and strategic partnerships, including international collaborations.
• David J. Swanberg's appointment as Chief Operating Officer leverages his 35+ years of experience in Radiochemical Processing, Medical Isotope Production, Nuclear Waste Management, Materials Science, Regulatory Affairs, and Project Management.
• Mr. Swanberg's prior role as Chief Technical Manager for Vivos Inc. since 2017 ensures continuity and deep involvement in product development, production, user training, regulatory submissions, and intellectual property development.
• Mr. Swanberg's background as a co-founder of IsoRay Medical Inc. and his leadership in FDA 510(k) submission/clearance and participation in over $30.0 million in capital financing rounds demonstrate a proven track record in the medical isotope industry.

Future Outlook

The appointments of Brad Allan Weeks and David J. Swanberg are expected to significantly contribute to Vivos Inc.'s growth in targeted cancer therapies, including business development, team expansion, strategic partnerships, and advancements in radionuclide therapies.

Management Comments

• Brad Allan Weeks is a seasoned leader with extensive experience in the medical device and biotechnology sectors.
• As President, Brad plays a pivotal role in business development, team expansion, and strategic partnerships, contributing to the Company’s growth in targeted cancer therapies that deliver radioactive agents directly to tumors while minimizing damage to healthy tissue.
• Brad has built a distinguished career in healthcare innovation, holding leadership positions at organizations focused on advancing medical technologies and patient outcomes.
• David J. Swanberg has over 35 years experience in Radiochemical Processing, Medical Isotope Production, Nuclear Waste Management, Materials Science, Regulatory Affairs, and Project Management.
• Mr. Swanberg has been actively engaged with the Company in his previous role as Chief Technical Manager since 2017 and has been integrally involved in product development, production, user training, regulatory submissions, and intellectual property development.

Industry Context

These appointments underscore Vivos Inc.'s commitment to strengthening its leadership in the highly specialized and competitive medical device and biotechnology sectors, particularly in targeted cancer therapies using radioactive agents. The focus on experienced professionals in business development, operations, and radiochemical processing aligns with the industry's demand for innovation and regulatory expertise in oncology.

Comparison to Industry Standards

• David J. Swanberg's experience as a co-founder and Executive Vice President of Operations for IsoRay Medical Inc., where he led the development and FDA clearance of the Cs-131 brachytherapy seed product, demonstrates a track record comparable to successful leaders in the medical isotope and brachytherapy industry.
• His participation in over $30.0 million in capital financing rounds for IsoRay Medical Inc. indicates experience in securing significant funding, a critical aspect for growth-stage biotechnology companies.
• Brad Allan Weeks' background in quality assurance and regulatory affairs, combined with an MBA in Technology Management, aligns with the industry's need for leaders who can navigate complex regulatory landscapes while driving technological innovation.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through enhanced leadership, strategic growth, and operational efficiency in a specialized market.
• Employees: New leadership may bring changes in organizational structure, strategic direction, and potentially new opportunities or challenges within the company.
• Customers: Expected improvements in product development and delivery of targeted cancer therapies, potentially leading to more effective solutions.
• Suppliers: Potential for new or adjusted relationships as the company's operational strategies evolve under new leadership.
• Creditors: Strengthened management team could improve the company's financial stability and growth prospects, positively impacting creditworthiness.

Next Steps

• Continued growth in targeted cancer therapies through enhanced business development and strategic partnerships.
• Advancement of radionuclide therapies and expansion of the IsoPet and RadioGel divisions.
• Ongoing product development, production, user training, regulatory submissions, and intellectual property development under new leadership.

Key Dates

Recommendation

The appointment of highly experienced and industry-veteran leaders like Brad Allan Weeks as President and David J. Swanberg as COO is a strong positive indicator for Vivos Inc. Mr. Weeks' expertise in business development and strategic partnerships, combined with Mr. Swanberg's deep technical and operational background in medical isotopes and regulatory affairs, significantly strengthens the company's executive team. Mr. Swanberg's prior success as a co-founder of IsoRay Medical Inc. and his involvement in substantial capital raises demonstrate a proven ability to drive growth and navigate complex industry landscapes. These strategic hires are expected to accelerate the company's progress in targeted cancer therapies, enhance operational efficiency, and potentially unlock new market opportunities, making the stock an attractive 'buy' for long-term investors.

Keywords

Vivos Inc., Brad Allan Weeks, David J. Swanberg, President, Chief Operating Officer, COO, Management Appointment, Medical Device, Biotechnology, Oncology, Cancer Therapy, Radioactive Agents, IsoPet, RadioGel, Radiochemical Processing, Medical Isotope, Regulatory Affairs, Leadership